Equities research analysts at BMO Capital Markets started coverage on shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) in a report released on Monday. The firm set an “outperform” rating and a $26.00 price target on the stock. BMO Capital Markets’ price target would indicate a potential upside of 100.00% from the company’s previous close.

Several other research firms also recently commented on RARX. SunTrust Banks Inc. initiated coverage on shares of Ra Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $32.00 target price on the stock. Jefferies Group initiated coverage on shares of Ra Pharmaceuticals in a research report on Monday. They set a “buy” rating on the stock. Finally, Credit Suisse Group AG initiated coverage on shares of Ra Pharmaceuticals in a research report on Monday. They set an “outperform” rating and a $19.00 target price on the stock.

Ra Pharmaceuticals (NASDAQ:RARX) opened at 13.00 on Monday. The stock has a 50 day moving average of $13.17 and a 200 day moving average of $13.17. Ra Pharmaceuticals has a 12-month low of $12.33 and a 12-month high of $14.86. The firm’s market cap is $7.20 million.

In other news, major shareholder Harry R. Weller purchased 338,462 shares of the stock in a transaction on Monday, October 31st. The stock was purchased at an average price of $13.00 per share, for a total transaction of $4,400,006.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Rajeev M. Shah purchased 161,538 shares of the stock in a transaction on Monday, October 31st. The shares were purchased at an average price of $13.00 per share, with a total value of $2,099,994.00. The disclosure for this purchase can be found here.

COPYRIGHT VIOLATION NOTICE: “BMO Capital Markets Initiates Coverage on Ra Pharmaceuticals Inc (RARX)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2016/11/23/bmo-capital-markets-initiates-coverage-on-ra-pharmaceuticals-inc-rarx.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

5 Day Chart for NASDAQ:RARX

Receive News & Stock Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.